Filing Overview
Source discrepancy: The supplied filing is Aeglea BioTherapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, not Spyre Therapeutics, Inc. The filing was signed February 24, 2020. Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics, led by pegzilarginase for Arginase 1 Deficiency.
Business Context and Reporting Period
Aeglea operated as a single reporting segment with 76 full-time employees at December 31, 2019. Its lead program, pegzilarginase, was in the global Phase 3 PEACE trial and a long-term open-label extension study. Other programs included ACN00177 for Homocystinuria, the preclinical AEB5100 cystinuria program, and oncology studies involving pegzilarginase.
The filing reports annual results for 2019, with comparative annual results for 2018 and 2017. Unaudited quarterly data are also provided for the quarters ended March 31, June 30, September 30, and December 31, 2019.
Financial Metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $0 | $3.9 million | Down $3.9 million |
| Research and development expense | $64.6 million | $36.7 million | Up 76% |
| General and administrative expense | $15.7 million | $12.6 million | Up 25% |
| Total operating expenses | $80.3 million | $49.4 million | Up 63% |
| Loss from operations | $80.3 million | $45.5 million | Loss increased $34.9 million |
| Interest income | $2.1 million | $1.2 million | Up 83% |
| Net loss | $78.3 million | $44.3 million | Loss increased $33.9 million |
| Basic and diluted loss per share | $2.45 | $2.13 | Loss per share increased |
| Operating cash flow | $(65.7) million | $(32.2) million | Cash use increased $33.5 million |
Revenue consisted solely of grant revenue from the Cancer Prevention and Research Institute of Texas. The $19.8 million grant was fully recognized over its term, which ended in May 2018; Aeglea had no product revenue.
At December 31, 2019, cash, cash equivalents, marketable securities, and restricted cash totaled $73.4 million, including $19.3 million of cash and cash equivalents, $52.7 million of marketable securities, and $1.5 million of restricted cash. Working capital was $56.1 million, total assets were $83.2 million, and total liabilities were $23.1 million. The company reported no debt or credit facility.
Financing activities provided $65.7 million in 2019, principally from a February 2019 public offering that generated $64.5 million of net proceeds. Investing activities used $1.7 million, including $1.5 million for property and equipment. Stockholders’ equity was $60.1 million, while accumulated deficit reached $195.1 million.
Material Changes Versus the Prior Comparable Period
- Revenue fell to zero because the CPRIT grant was completed and fully collected in 2018.
- Research and development spending increased by $27.9 million, primarily from manufacturing and pre-commercial investment in pegzilarginase, increased ACN00177 manufacturing, Phase 3 and extension-study activity, oncology trial activity, and expanded personnel.
- General and administrative expense increased by $3.1 million due to additional personnel, compensation, office space, and public-company costs.
- Net loss increased 76% to $78.3 million, reflecting higher development spending and the absence of grant revenue.
- Operating cash use more than doubled to $65.7 million, while year-end liquidity declined modestly from $74.5 million to $73.4 million.
- The company adopted the new lease standard, ASC Topic 842, on January 1, 2019, recognizing operating lease right-of-use assets and lease liabilities.
- Aeglea entered a new approximately 30,000-square-foot Austin headquarters and laboratory lease expiring in April 2028. Total contractual lease payments at year-end were $9.2 million, including operating and finance leases.
Guidance, Outlook, Risks, and Unusual Items
- Management expected PEACE enrollment to be completed in the third quarter of 2020 and topline data to be available in the first quarter of 2021.
- A Phase 1/2 trial of ACN00177 for Homocystinuria was expected to begin in the second quarter of 2020, with initial data expected in the first quarter of 2021.
- Management expected to submit an IND or CTA for the AEB5100 cystinuria program in the second half of 2020.
- Based on its operating plan, management estimated that available liquidity would fund operations through the first quarter of 2021. The filing states that additional financing would be required to execute all planned research and development activities.
- Pegzilarginase had FDA and EMA Orphan Drug Designations, FDA Fast Track and Breakthrough Therapy Designations, and FDA Rare Pediatric Disease designation. These designations did not assure approval or commercial success.
- Clinical risks included failure to demonstrate clinical benefit, reliance on plasma arginine as the primary PEACE endpoint, use of mobility assessments that had not been validated specifically for Arginase 1 Deficiency, enrollment challenges in rare-disease populations, and potential adverse events including hypersensitivity and hyperammonemia.
- The company had no approved products, no product revenue, and expected continuing losses. It relied on third parties for clinical research, manufacturing, testing, storage, and distribution.
- Other risks included additional capital requirements, dilution from future equity financing, regulatory delays, manufacturing or supply failures, competition, intellectual-property challenges, reimbursement uncertainty, and potential limitations on the use of tax attributes.
- License obligations included potential milestone payments of up to $6.4 million per licensed product candidate, a $5.0 million payment upon regulatory approval of a product, low-single-digit royalties on net sales, and revenue sharing on certain sublicense consideration.
Facts Investors Should Verify
- Confirm the issuer identity: the filing is for Aeglea BioTherapeutics, Inc., whereas the request identifies Spyre Therapeutics, Inc.
- Verify the actual 2019 Form 10-K and whether a later corporate name, ticker, merger, or restructuring affects comparability.
- Review the Phase 3 PEACE trial enrollment, endpoint results, regulatory interactions, and any subsequent approval or discontinuation events.
- Reconcile the stated liquidity runway through the first quarter of 2021 with subsequent financing, cash-burn, and clinical-development disclosures.
- Assess the effect of future equity issuance and the 4 million pre-funded warrants sold in February 2019 on dilution.
- Review manufacturing commitments, supply concentration, third-party contract terms, and lease obligations.
- Evaluate the validity of estimated patient populations, market opportunity, reimbursement assumptions, intellectual-property coverage, and potential license and CPRIT royalty obligations.